Results 231 to 240 of about 6,202,090 (405)
Molecular Oncology, Volume 19, Issue 5, Page 1332-1346, May 2025.Consensus molecular subtypes (CMS1‐4) have been identified to study colorectal cancer heterogeneity and serve as potential biomarkers. In this study, we developed and evaluated NanoCMSer, a NanoString‐based classifier using 55 genes, optimized for FF and FFPE to facilitate the clinical evaluation of CMS subtyping.
Arezo Torang +10 more
wiley +1 more source
Molecular Oncology, EarlyView.Tumor microenvironment drives cancer formation and progression. We analyzed the role of human cancer‐associated adipocytes from patients with renal cell carcinoma (RCC) stratified as lean, overweight, or obese. RNA‐seq demonstrated that, among the most altered genes involved in the tumor–stroma crosstalk, are ADAM12 and CYP1B1, which were proven to be ...
Sepehr Torabinejad +13 more
wiley +1 more source
Molecular Oncology, Volume 19, Issue 4, Page 1188-1202, April 2025.Male infertility is a known risk factor for the development of testicular cancer. In this paper, we analyzed the expression profile of a microRNA panel by real‐time PCR and validated the results by digital PCR. Experimental and bioinformatics analyses allowed us to identify possible biomarkers able to discern men with a higher risk of developing ...
Carmen Ferrara +14 more
wiley +1 more source
Calcium signalling: Sphingosine kinase versus phospholipase C? [PDF]
, 1996 Michael A. Beaven
openalex +1 more source
Multi‐omics profiling reveals key factors involved in Ewing sarcoma metastasis
Molecular Oncology, Volume 19, Issue 4, Page 1002-1028, April 2025.Using a mouse model that recapitulates the spread of tumor cells within the body, we have profiled paired tumors and metastasis samples using a multiomics approach combining different layers of biological information. We identified key genes that drive metastasis in Ewing sarcoma.
Mariona Chicón‐Bosch +11 more
wiley +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, Volume 19, Issue 5, Page 1404-1421, May 2025.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source